Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models

Shun ichi Yamaguchi, Sean D. Donevan, Michael A Rogawski

Research output: Contribution to journalArticle

121 Scopus citations

Abstract

The anticonvulsant activities of a noncompetitive (GYKI 52466) and a competitive (NBQX) AMPA/kainate antagonist were compared in the maximal electroshock (MES) seizure test and various chemoconvulsant models. Both antagonists were protective in the MES and pentylenetetrazol tests. GYKI 52466 was also protective against seizures and lethality induced by 4-aminopyridine, kainate and AMPA, but not by NMDA, whereas NBQX was ineffective in these chemoconvulsant tests. Both GYKI 52466 and NBQX produced motor impairment at doses similar to those that were protective in the MES test. Under some circumstances, noncompetitive AMPA/kainate antagonists could offer advantages over competitive antagonists in seizure therapy. However, neurological toxicity is an obstacle to the potential clinical use of both classes of agents.

Original languageEnglish (US)
Pages (from-to)179-184
Number of pages6
JournalEpilepsy Research
Volume15
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Keywords

  • Anticonvulsant drugs
  • Competitive and non-competitive non-NMDA antagonists
  • Experimental seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Fingerprint Dive into the research topics of 'Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models'. Together they form a unique fingerprint.

  • Cite this